Myxedema Coma Market - Growth Drivers and Challenges
Growth Drivers
- Growing Incidence of Pneumonia- Untreated hypothyroidism can affect the immune system making patients more prone to pneumonia which might increase the risk of the development of myxedema coma.
Globally, More than 650,000 children under the age of five lose their lives to pneumonia every year, including more than 150,000 newborns. - Spiking Prevalence of Chronic Stress- Pre-existing medical conditions may become worse under prolonged stress, and fluctuations in hormones can be brought on by both short-term and long-term stress which can affect the hypothalamic-pituitary-adrenal axis impacting the thyroid hormone production, leading to an increase risk of developing myxedema coma.
According to statistics, in the UK more than 150,000 people die each year from a stress-related ailment. - Increasing Cases of Urine Infections- One of the most typical bacterial infections is UTIs, which may be brought on by bacterial or fungal infections. If UTI is left untreated it may become worse and lead to the development of conditions such as myxedema coma.
Every year, over 140 million people worldwide are affected by urinary tract infections (UTIs). - Rising Surgical Procedures- Surgical procedures are an excellent choice for treating most ailments owing to the benefits and outcomes provided. Anesthesia is frequently administered during surgical procedures, which can cause severe, potentially fatal myxedema by impairing the thyroid gland's ability to function normally.
According to the World Health Organization (WHO), millions of individuals undergo surgery every year, and it is estimated that surgical procedures account for 13% of all disability-adjusted life years worldwide.
Challenges
-
High Cost of Treatment– Owing to the frequent need for hospitalization and extensive care, myxedema coma therapy could be costly. The expense of hospitalization could be significant since myxedema coma is often treated in a medical facility, which may include the price of hospital lodging, medical personnel, and medical equipment. Additionally, patients may require continuous care and monitoring after treatment for myxedema coma.
-
Limited Awareness Among People
- Lack of Specific Treatment
Myxedema Coma Market Size and Forecast:
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
4.6% |
|
Base Year Market Size (2025) |
USD 2.35 billion |
|
Forecast Year Market Size (2035) |
USD 3.68 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of myxedema coma is estimated at USD 2.45 billion.
The global myxedema coma market size was around USD 2.35 billion in 2025 and is likely to expand at a CAGR of more than 4.6%, surpassing USD 3.68 billion revenue by 2035.
By 2035, North America is projected to capture a 38% share of the myxedema coma market, impelled by the growing prevalence of obesity.
Key players in the market include AbbV, ie Inc., Merck & Co., Inc., Pfizer Inc., GSK plc., Sanofi Global, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Lannett Company, Inc., Zydus Lifesciences.
